PL3065828T3 - Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych - Google Patents

Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych

Info

Publication number
PL3065828T3
PL3065828T3 PL14860231T PL14860231T PL3065828T3 PL 3065828 T3 PL3065828 T3 PL 3065828T3 PL 14860231 T PL14860231 T PL 14860231T PL 14860231 T PL14860231 T PL 14860231T PL 3065828 T3 PL3065828 T3 PL 3065828T3
Authority
PL
Poland
Prior art keywords
materials
methods
hematological malignancies
treating hematological
treating
Prior art date
Application number
PL14860231T
Other languages
English (en)
Inventor
Ayalew Tefferi
Original Assignee
Mayo Foundation For Medical Education And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation For Medical Education And Research filed Critical Mayo Foundation For Medical Education And Research
Publication of PL3065828T3 publication Critical patent/PL3065828T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/22Haematology
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL14860231T 2013-11-06 2014-11-05 Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych PL3065828T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361900854P 2013-11-06 2013-11-06
US201361904195P 2013-11-14 2013-11-14
EP14860231.1A EP3065828B1 (en) 2013-11-06 2014-11-05 Methods and materials for treating hematological malignancies
PCT/US2014/064112 WO2015069758A1 (en) 2013-11-06 2014-11-05 Methods and materials for treating hematological malignancies

Publications (1)

Publication Number Publication Date
PL3065828T3 true PL3065828T3 (pl) 2019-06-28

Family

ID=53042029

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14860231T PL3065828T3 (pl) 2013-11-06 2014-11-05 Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych

Country Status (17)

Country Link
US (1) US11123359B2 (pl)
EP (2) EP3539547A1 (pl)
JP (1) JP6532478B2 (pl)
AU (1) AU2014346840B2 (pl)
CA (1) CA2929809C (pl)
CY (1) CY1122229T1 (pl)
DK (1) DK3065828T3 (pl)
ES (1) ES2717777T3 (pl)
HR (1) HRP20190538T1 (pl)
HU (1) HUE042792T2 (pl)
LT (1) LT3065828T (pl)
PL (1) PL3065828T3 (pl)
PT (1) PT3065828T (pl)
RS (1) RS58659B1 (pl)
SI (1) SI3065828T1 (pl)
SM (1) SMT201900185T1 (pl)
WO (1) WO2015069758A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
KR20250151565A (ko) * 2017-07-28 2025-10-21 제론 코포레이션 골수형성이상 증후군의 치료 방법
UA129979C2 (uk) * 2018-07-31 2025-10-01 Джерон Корпорейшн Способи ідентифікації пацієнтів з мієлофіброзом, що мають підвищену ймовірність отримати користь від лікування іметелстатом
AU2019389005B2 (en) 2018-11-29 2024-06-20 Geron Corporation Methods of treating myelodysplastic syndrome
KR20230041707A (ko) * 2020-07-17 2023-03-24 제론 코포레이션 피하 텔로머라제 억제제 조성물 및 이의 사용 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4474480A2 (en) 2006-10-30 2024-12-11 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
WO2011098901A1 (en) * 2010-02-12 2011-08-18 Ipsogen Asxl1 as a new diagnostic marker of myeloid neoplasms
KR20250086805A (ko) 2011-10-19 2025-06-13 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US9474689B2 (en) * 2011-10-25 2016-10-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2013151983A1 (en) * 2012-04-02 2013-10-10 The Cleveland Clinic Foundation Methods for predicting the prognosis of a subject with a myeloid malignancy
US9375485B2 (en) * 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
HRP20240624T1 (hr) 2012-12-07 2024-08-02 Geron Corporation Inhibitor telomeraze imetelstat za liječenje mijeloproliferativnih poremećaja i mijeloproliferativne neoplazme
UA129979C2 (uk) 2018-07-31 2025-10-01 Джерон Корпорейшн Способи ідентифікації пацієнтів з мієлофіброзом, що мають підвищену ймовірність отримати користь від лікування іметелстатом

Also Published As

Publication number Publication date
JP6532478B2 (ja) 2019-06-19
LT3065828T (lt) 2019-04-10
RS58659B1 (sr) 2019-05-31
ES2717777T3 (es) 2019-06-25
HUE042792T2 (hu) 2019-07-29
SMT201900185T1 (it) 2019-05-10
EP3065828A4 (en) 2017-07-19
HRP20190538T1 (hr) 2019-05-17
JP2016537423A (ja) 2016-12-01
CA2929809A1 (en) 2015-05-14
EP3065828B1 (en) 2019-01-09
EP3539547A1 (en) 2019-09-18
DK3065828T3 (en) 2019-04-15
US20160287625A1 (en) 2016-10-06
AU2014346840A1 (en) 2016-06-02
CA2929809C (en) 2022-05-17
CY1122229T1 (el) 2020-11-25
WO2015069758A1 (en) 2015-05-14
AU2014346840B2 (en) 2020-02-06
SI3065828T1 (sl) 2019-04-30
US11123359B2 (en) 2021-09-21
PT3065828T (pt) 2019-04-01
EP3065828A1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
IL281058A (en) Compositions and methods for treating anemia
IL245778B (en) Methods and preparations for the treatment of hemophilia
IL245281A0 (en) Methods and preparations for the treatment of cancer
PT3556775T (pt) Anticorpos anti-lag-3 para tratar neoplasias malignas hematológicas
SG11201603050TA (en) Methods for treating cancers
GB201420103D0 (en) Treating particles
IL244118A0 (en) Compounds and methods for the treatment of chronic urticaria
GB201305414D0 (en) Method and composition
IL244353A0 (en) Compounds and use for cancer treatment
PL2967127T3 (pl) Sposoby redukcji jednej lub więcej nitrozoamn właściwych dla tytoniu w materiale tytoniowym
GB201312318D0 (en) Novel methods and compounds
SMT201900185T1 (it) Metodi e materiali per trattare neoplasie maligne ematologiche
HUE048625T2 (hu) Módszer rák kezelésére
PL3071192T3 (pl) Związek kurkufenol do zastosowania w leczeniu nowotworu
EP3065755A4 (en) Methods for treating hematological malignancies
PL2964334T3 (pl) Kompozycje i sposoby do zabiegów dla uszkodzonych włosów
GB2515316B (en) Methods for composite material processing
GB201411429D0 (en) Methods for monitoring treatment response and relapse in ovarian cancer
IL246069B (en) Preparations and methods for the treatment of malignant blood diseases
IL246185A0 (en) Methods and compositions for treating dysregulation in systems
GB2519829B (en) Methods for monitoring treatment response and relapse in breast cancer
GB201314922D0 (en) Materials and methods for treating ARID1A deficent Cancer
ZA201408732B (en) Composition and methods for treating wounds
GB201319951D0 (en) Treating Particle